25 results for «103»

Filter By

25 results

Transcatheter options for degenerated surgical aortic valves - LIVE case

08 Feb 2025 – From PCR Tokyo Valves 2025

A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

Transcatheter options for degenerated surgical aortic valves - LIVE case

Transcatheter management of failed THV - LIVE case

09 Feb 2025 – From PCR Tokyo Valves 2025

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Transcatheter management of failed THV - LIVE case

Advanced mitral TEER - LIVE case

24 Nov 2024 – From PCR London Valves 2024

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

  • A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...
Advanced mitral TEER - LIVE case

Transcatheter tricuspid valve replacement - LIVE case

15 May 2024 – From EuroPCR 2024

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

Transcatheter tricuspid valve replacement

Imaging-guided left main PCI - LIVE case

17 May 2024 – From EuroPCR 2024

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

Imaging-guided left main PCI

Predictors of haemodynamic structural valve deterioration following transcatheter aortic valve implantation

02 Mar 2020

Elevated gradients have been proposed to be associated with haemodynamic structural valve deterioration (SVD) after transcatheter aortic valve implantation (TAVI); however, data regarding their characterisation remain scarce. This study sought to investigate the prevalence and predictors of moderate or greater SVD and the prevalence of valve...

Authors :

T. Rheude, C. Pellegrini, S. Cassese, J.Wiebe, S. Wagner, T.Trenkwalder, H. Alvarez,, N. P. Mayr, C. Hengstenberg, H. Schunkert, A. Kastrati, O. Husser, M. Joner
EuroIntervention: Predictors of haemodynamic structural valve deterioration following transcatheter aortic valve implantation

Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry

17 Sep 2022

Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.

Elad Asher

Author

Elad Asher
Percutaneous or Surgical Management of Post-Infarction Ventricular Septal Defects: The United Kingdom National Registry

Elixir Medical completes enrollment in BIOADAPTOR randomized controlled trial of Dynamx Coronary Bioadaptor System

15 Feb 2022

Dynamx bioadaptor restores rotational motion and vessel stress reduction in new study

02 Jun 2022

EXpansion of stents after Intravascular lithoTripsy versus conventional predilatation in CALCified coronary arteries: the EXIT-CALC – a prospective, randomized study

20 Sep 2022

Pierre Deharo and Michele Pighi share with us their views on the EXIT-CALC study presented by Thomas Oomens at TCT 2022.

Pierre Deharo

Author

Pierre Deharo
M. Pighi

Author

Michele Pighi
EXpansion of stents after Intravascular lithoTripsy versus conventional predilatation in CALCified coronary arteries: the EXIT-CALC – a prospective, randomized study

OPTIMIZE IDE: A randomized trial of a novel, ultra low profile fixed-wire DES

26 Oct 2020

At TCT Connect 2020, Late-Breaking Trial Session IV, the primary results of the OPTIMIZE IDE were presented by Dean J. Kereiakes. Daniele Giacoppo provides a summary of the trial.

Daniele Giacoppo

Author

Daniele Giacoppo
Live from TCT Connect 2020: The OPTIMIZE trial

RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

05 Sep 2023

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Alessandro Sticchi

Author

Alessandro Sticchi
RIVER: Rivaroxaban for valvular heart disease and atrial fibrillation

EuroPCR 2024 – One-month DAPT followed by 5-month Ticagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

15 May 2024

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical...

EuroPCR 2024: Primary outcomes from PINNACLE I clinical trial establish safety and effectiveness of Elixir Medical’s Hertz Contact Intravascular Lithotripsy System for calcium fragmentation in moderate to severe calcified coronary artery lesions

16 May 2024

SENIOR-RITA - Older patients with non-ST segment elevation myocardial infarction randomised interventional treatment trial

02 Sep 2024

Mirvat Alasnag provides her take on the SENIOR-RITA trial, presented by Vijay Kunadian at the ESC Congress 2024 in London.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
SENIOR-RITA

Cool AMI EU pivotal trial- final results after trial discontinuation following ad interim analysis

18 May 2021

Results of the interim analyses performed after 12 months in the first 111 patients enrolled in phase II Cool AMI trial evaluating safety and effectiveness of systemic therapeutic hypothermia as an adjunctive therapy in anterior STEMI undergoing PCI as compared to PCI only. Analyses showed significant...

Cool AMI EU pivotal trial- final results after trial discontinuation following ad interim analysis

ECMO-CS – Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: primary results from the multicenter, randomized ECMO-CS trial

07 Nov 2022

Mirvat Alasnag provides her take on the ECMO-CS trial, which was presented during AHA 2022 in Chicago, and simultaneously published in Circulation. 

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
ECMO-CS – Extracorporeal membrane oxygenation in the therapy of cardiogenic shock: primary results from the multicenter, randomized ECMO-CS trial

OPTION – Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation

08 Nov 2022

Ali Nazmi Calik provides his take on OPTION, which was presented during AHA 2022 in Chicago.

Author

Ali Nazmi Calik
OPTION – Indobufen or aspirin on top of clopidogrel after coronary drug-eluting stent implantation

SCOPE II: A randomized trial of two self-expanding TAVR bioprostheses

18 Oct 2020

At TCT Connect 2020, Late-Breaking Trial Session II, the primary results of the Safety and Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation (SCOPE) 2 trial were presented and simultaneously published in Circulation. Daniele Giacoppo provides a summary of the trial.

Daniele Giacoppo

Author

Daniele Giacoppo
Live from TCT Connect 2020: The SCOPE II trial

Future directions of drug-coated balloon angioplasty

06 Feb 2025

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Dr. F. Alfonso

Author

Fernando Alfonso
Javier Cuesta

Author

Javier Cuesta
Future directions of drug-coated balloon angioplasty
Didn’t find what you were looking for?